MHC class II expression in pancreatic tumors: A link to intratumoral inflammation

Virchows Archiv

Volumn 460, Issue 1, 2012, Pages 47-60

  Gaida, Matthias M ^a   Welsch, Thilo ^a   Herpel, Esther ^a   Tschaharganeh, Darjus F ^a   Fischer, Lars ^a   Schirmacher, Peter ^a   Hänsch, G Maria ^a   Bergmann, Frank ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Intratumoral inflammation; MHC class II; Pancreatic cancer; Pancreatic endocrine tumor; T cell proliferation

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STAPHYLOCOCCUS ENTEROTOXIN B;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; PANCREAS TUMOR; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84857039699     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-011-1175-x     Document Type: Article

References (60)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249
2. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70 (Pubitemid 30046295)
3. Kleeff J, Beckhove P, Esposito I, Herzig S, Huber PE, Lohr JM, Friess H (2007) Pancreatic cancer microenvironment. Int J Cancer 121(4):699-705 (Pubitemid 47106197)
4. Welsch T, Kleeff J, Friess H (2007) Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med 7 (5):504-521 (Pubitemid 47244895)
5. Greer JB, Whitcomb DC (2009) Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol 9 (4):411-418
6. Tingstedt B, Johansson P, Andersson B, Andersson R (2007) Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response. Scand J Gastroenterol 42(6):754-759 (Pubitemid 46763583)
7. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, Bevilacqua G, Campani D (2004) Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57(6):630-636 (Pubitemid 38725766)
8. Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G, Buemi M (2010) Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 288(1):10-16
9. Schmitz-Winnenthal FH, Escobedo LV, Beckhove P, Schirrmacher V, Bucur M, Ziouta Y, Volk C, Schmied B, Koch M, Antolovic D, Weitz J, Buchler MW, Z'Graggen K (2006) Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma. Int J Oncol 28(6):1419-1428
10. Wente MN, Gaida MM, Mayer C, Michalski CW, Haag N, Giese T, Felix K, Bergmann F, Giese NA, Friess H (2008) Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol 33(2):297-308
11. Gaida MM, Gunther F, Wagner C, Friess H, Giese NA, Schmidt J, Hansch GM, Wente MN (2008) Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections. Clin Exp Immunol 154 (2):216-223
12. Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, Giese NA, Buchler MW, Friess H (2008) CXCL14 expression and potential function in pancreatic cancer. Cancer Lett 259(2):209-217 (Pubitemid 350251641)
13. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, Kawaguchi M, Kobayashi H, Doi R, Hori T, Fujii N, Imamura M (2000) Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 6(9):3530-3535
14. Scupoli MT, Sartoris S, Tosi G, Ennas MG, Nicolis M, Cestari T, Zamboni G, Martignoni G, Lemoine NR, Scarpa A, Accolla RS (1996) Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens 48(4 Pt 1):301-311 (Pubitemid 26377570)
15. Berghuis D, de Hooge AS, Santos SJ, Horst D, Wiertz EJ, van Eggermond MC, van den Elsen PJ, Taminiau AH, Ottaviano L, Schaefer KL, Dirksen U, Hooijberg E, Mulder A, Melief CJ, Egeler RM, Schilham MW, Jordanova ES, Hogendoorn PC, Lankester AC (2009) Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol 218(2):222-231
16. Townsend A, Bodmer H (1989) Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7:601-624 (Pubitemid 19138026)
17. Albanesi C, Cavani A, Girolomoni G (1998) Interferon-gammastimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II molecules. J Invest Dermatol 110(2):138-142 (Pubitemid 28105847)
18. Fais S, Capobianchi MR, Marcheggiano A, Iannoni C, Pallone F (1992) MHC class II antigens on the epithelial cells of the human gastrointestinal tract. Gastroenterology 102(1):377-378
19. Ruiter DJ, Bergman W, Welvaart K, Scheffer E, van Vloten WA, Russo C, Ferrone S (1984) Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 44(9):3930-3935 (Pubitemid 14041618)
20. Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Muller M, Kramer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanovic S (2006) Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 12(14 Pt 1):4163-4170
21. Walsh MD, Dent OF, Young JP, Wright CM, Barker MA, Leggett BA, Bokey L, Chapuis PH, Jass JR,Macdonald GA (2009)HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers. Int J Cancer 125 (5):1231-1237
22. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F (1991) Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 2(1):47-54
23. Esteban F, Concha A, Huelin C, Perez-Ayala M, Pedrinaci S, Ruiz-Cabello F, Garrido F (1989) Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer 43(3):436-442 (Pubitemid 19092326)
24. Andersen SN, Rognum TO, Lund E, Meling GI, Hauge S (1993) Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. Br J Cancer 68(1):80-85 (Pubitemid 23178555)
25. Pandha H, Rigg A, John J, Lemoine N (2007) Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines. Clin Exp Immunol 148(1):127-135 (Pubitemid 46364984)
26. Radsak M, Iking-Konert C, Stegmaier S, Andrassy K, Hansch GM (2000) Polymorphonuclear neutrophils as accessory cells for T-cell activation: major histocompatibility complex class II restricted antigen-dependent induction of T-cell proliferation. Immunology 101(4):521-530 (Pubitemid 32001467)
27. Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) (2010) World Health Organisation classification of tumours. Pathology and genetics of tumours of the digestive system. Ductal adenocarcinoma of the pancreas. IARC Press, Lyon
28. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours, 7th edition. Wiley, Oxford
29. Heitz PU, Komminoth P, Perren A (2004) Tumours of endocrine organs: pathology and genetics World Health Organisation classification of tumors. IARC press, Lyon
30. Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) World Health Organisation classification of tumours. Pathology and genetics of tumours of the digestive system. Neuroendocrine neoplasms of the pancreas. IARC press, Lyon
31. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395-401 (Pubitemid 44451313)
32. Bergmann F, Breinig M, Hopfner M, Rieker RJ, Fischer L, Kohler C, Esposito I, Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P, Kern MA (2009) Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol 104(1):171-181
33. Ceyhan GO, Bergmann F, Kadihasanoglu M, Erkan M, Park W, Hinz U, Giese T, Muller MW, Buchler MW, Giese NA, Friess H (2007) The neurotrophic factor artemin influences the extent of neural damage and growth in chronic pancreatitis. Gut 56(4):534-544 (Pubitemid 46580510)
34. Bijen CB, Bantema-Joppe EJ, de Jong RA, Leffers N, Mourits MJ, Eggink HF, van der Zee AG, Hollema H, de Bock GH, Nijman HW (2010) The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer 126(6):1417-1427
35. Rolland P, Deen S, Scott I, Durrant L, Spendlove I (2007) Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res 13 (12):3591-3596 (Pubitemid 46955120)
36. Itano AA, Jenkins MK (2003) Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 4(8):733-739 (Pubitemid 36986756)
37. Rocha N, Neefjes J (2008) MHC class II molecules on the move for successful antigen presentation. EMBO J 27(1):1-5
38. Radfar S, Wang Y, Khong HT (2009) Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J Immunol 183(10):6800-6807
39. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16(2):91-102
40. Han DC, Huang GT, Lin LM, Warner NA, Gim JS, Jewett A (2003) Expression of MHC Class II, CD70, CD80, CD86 and proinflammatory cytokines is differentially regulated in oral epithelial cells following bacterial challenge. Oral Microbiol Immunol 18(6):350-358 (Pubitemid 37372895)
41. Giacomini P, Tecce R, Gambari R, Sacchi A, Fisher PB, Natali PG (1988) Recombinant human IFN-gamma, but not IFN-alpha or IFN-beta, enhances MHC- and non-MHC-encoded glycoproteins by a protein synthesis-dependent mechanism. J Immunol 140 (9):3073-3081
42. Tang KF, Chan SH, Loh KS, Chong SM, Wang D, Yeoh KH, Hu H (1999) Increased production of interferon-gamma by tumour infiltrating T lymphocytes in nasopharyngeal carcinoma: indicative of an activated status. Cancer Lett 140(1-2):93-98 (Pubitemid 29251318)
43. Schmitz-Winnenthal FH, Volk C, Z'Graggen K, Galindo L, Nummer D, Ziouta Y, Bucur M, Weitz J, Schirrmacher V, Buchler MW, Beckhove P (2005) High frequencies of functional tumorreactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 65(21):10079-10087 (Pubitemid 41541490)
44. Monti P, Marchesi F, Reni M, Mercalli A, Sordi V, Zerbi A, Balzano G, Di Carlo V, Allavena P, Piemonti L (2004) A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch 445(3):236-247 (Pubitemid 39286891)
45. Nickoloff BJ, Mitra RS, Green J, Shimizu Y, Thompson C, Turka LA (1993) Activated keratinocytes present bacterial-derived superantigens to T lymphocytes: relevance to psoriasis. J Dermatol Sci 6(2):127-133 (Pubitemid 23341346)
46. Schulz H, Karau A, Filsinger S, Schoels M, Kabelitz D, Richter R, Hansch GM (1998) Tubular epithelial cells as accessory cells for superantigen-induced T cell activation. Exp Nephrol 6(1):67-73 (Pubitemid 28096339)
47. Kraft M, Filsinger S, Kramer KL, Kabelitz D, Hansch GM, Schoels M (1995) Synovial fibroblasts as accessory cells for staphylococcal enterotoxin-mediated T-cell activation. Immunology 85(3):461-466
48. Fanger NA, Liu C, Guyre PM, Wardwell K, O'Neil J, Guo TL, Christian TP, Mudzinski SP, Gosselin EJ (1997) Activation of human T cells by major histocompatability complex class II expressing neutrophils: proliferation in the presence of superantigen, but not tetanus toxoid. Blood 89(11):4128-4135 (Pubitemid 27220961)
49. Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Forster I, Huss R, Weber WA, Kneilling M, Rocken M (2008) TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13 (6):507-518 (Pubitemid 351763899)
50. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B (2000) Tumor-specific CD4+ T cells have a major "post- licensing" role in CTL mediated anti-tumor immunity. J Immunol 165(11):6047-6055
51. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T,Morikawa T, Okushiba S, Kondo S, KatohH (2004) CD8+ tumor-infiltrating lymphocytes together with CD4+ tumorinfiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28(1):e26-e31
52. Lindner R, Unanue ER (1996) Distinct antigen MHC class II complexes generated by separate processing pathways. EMBO J 15(24):6910-6920 (Pubitemid 27023262)
53. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363(9414):1049-1057 (Pubitemid 38410779)
54. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA (2006) Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42(6):768-778
55. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7):1303-1310 (Pubitemid 26102328)
56. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B, Kalthoff H (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7(3 Suppl):925s-932s (Pubitemid 33600947)
57. Ye X, Kralli A, Ge R, Ricciardi RP, Knowles BB (1994) Down-regulation of MHC class I antigen in insulinoma cells controlled by the R1 element of the H-2 enhancer. Oncogene 9(4):1195-1204 (Pubitemid 24095029)
58. Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, Gimmon Z, Elias O, David IB, Kuznetz A, Shiloni E, Peretz T (2009) Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells. Clin Cancer Res 15(15): 4968-4977
59. Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N, Gatter K, Talbot DC, Harris AL, Ganesan TS (2003) Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res 9(1):84-92 (Pubitemid 36109719)
60. Schwartz RH (1996) Models of T cell anergy: is there a common molecular mechanism? J Exp Med 184(1):1-8 (Pubitemid 26247209)